BioCryst Pharmaceuticals to Present New Data on ORLADEYO® for Hereditary Angioedema at EAACI 2025 Meeting

BioCryst Pharmaceuticals will present new data on ORLADEYO, its oral treatment for hereditary angioedema (HAE), at the EAACI meeting in June 2025. The presentations will cover ORLADEYO's impact on quality of life, patient perceptions, long-term effectiveness, tolerability, and effects on pediatric patients; ORLADEYO is the first oral therapy for HAE prophylaxis in patients 12 and older, with potential side effects including abdominal pain and gastrointestinal issues, and QT prolongation at higher doses.

Analysis

BioCryst Pharmaceuticals (BCRX) is poised to present new data on ORLADEYO®, its oral, once-daily prophylactic treatment for hereditary angioedema (HAE), at the European Academy of Allergy and Clinical Immunology (EAACI) meeting from June 13-16, 2025. The four abstracts will cover ORLADEYO's impact on quality of life, patient perceptions, long-term effectiveness and tolerability, and its effects on pediatric patients, potentially enhancing the drug's credibility and visibility within the medical community. ORLADEYO holds a distinct market position as the first oral therapy specifically for HAE prophylaxis in patients aged 12 and older. However, its profile includes limitations, such as its ineffectiveness for acute HAE attacks and a list of common adverse reactions including abdominal pain, vomiting, and diarrhea, alongside concerns regarding QT prolongation at dosages above the recommended 150mg. Recent insider activity indicates a single sale of 7,000 shares by Nancy J Hutson for approximately $52,780 within the last six months, with no insider purchases reported. Institutional ownership data from Q1 2025 reveals a divergence in sentiment: 143 institutions added to their positions, with notable increases from Millennium Management LLC (+3.02M shares) and UBS Group AG (+2.16M shares), while 118 reduced stakes, including significant sales by Avoro Capital Advisors LLC (-3.17M shares) and Deerfield Management Company, L.P. (-2.95M shares). Analyst coverage includes an "Outperform" rating issued by RBC Capital on May 6, 2025, suggesting some optimism despite the mixed institutional signals.

Key Decisions for Investors

• Investors should closely monitor the data presented at the EAACI meeting in mid-June 2025, as positive findings, particularly on quality of life and pediatric use, could serve as a significant near-term catalyst for BCRX.
• Carefully weigh ORLADEYO's first-to-market advantage as an oral HAE prophylactic against its established limitations, including side effect profile and non-suitability for acute attacks, which may influence its long-term market penetration and competitive positioning.
• Consider the mixed institutional investment activity and the minor insider sale alongside the upcoming clinical data when evaluating positions, and look for subsequent commentary on commercial uptake and impact on physician prescribing habits.